? ?Lidocaine Hydrochloride (CAS 6108-05-0) | USP-Grade Local Anesthetic & Antiarrhythmic Agent? ?

?? ?Product Overview?

?Lidocaine Hydrochloride? (CAS 6108-05-0), also known as ?Lignocaine HCl monohydrate?, is a high-purity ?amide-class local anesthetic? and ?antiarrhythmic drug? with the molecular formula ?C??H??N?O·HCl·H?O? and a molecular weight of ?288.81?. This white crystalline powder (≥99% purity) is widely used in clinical settings for rapid pain relief and cardiac arrhythmia management. It exhibits strong penetration, fast onset (5 minutes), and prolonged duration (1–1.5 hours), making it 2× more potent than procaine with lower toxicity.

?Key Functions?:

• Induces local anesthesia for surgical and diagnostic procedures.

• Stabilizes cardiac membranes to treat ventricular arrhythmias.

• Serves as a reference standard in pharmaceutical quality control.

?Target Industries?: Pharmaceuticals, hospitals, veterinary medicine, and research labs.

? ?Key Advantages?

?? ?Applications?

• ?Surgical Anesthesia?

  : Topical creams, injectables for minor surgeries and dental procedures.

• ?Cardiac Care?

  : Intravenous use for ventricular tachycardia and fibrillation.

• ?Pharmaceutical R&D?

  : Impurity profiling and API synthesis in drug development.

?? ?Quality Assurance?

• ?Certifications?

  : Complies with 

  ?USP/EP?

   pharmacopeial standards and 

  ?ISO 9001?

  .

• ?Testing?

  : Validated via HPLC, NMR, and FTIR.

• ?Packaging?

  : Available in 

  ?25kg?

   bulk drums or smaller R&D batches (10mg–1kg).

?? ?Market Insights?

The global local anesthetics market is projected to grow at ?6.1% CAGR (2025–2030)?, driven by increasing surgical volumes and demand for non-opioid pain management. Lidocaine remains a cornerstone in emergency medicine, with ?Asia-Pacific? leading adoption due to expanding healthcare infrastructure and cost-effective manufacturing.